Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Highlights Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or 64Cu) isotope. The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capacity, which translates into more than 18,000 patient...
ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone
Showcasing at ASCRS 2025: More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons. ZEISS MEL 90 broadens refractive...
Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum’s Disease at World Orphan Drug Congress USA 2025
CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World Orphan Drug Congress USA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum's Disease Treatment. The Phase 2 topline results met all primary and secondary endpoints, with 64.5% of painful lipomas showing ≥ 50% dimension reduction or...
Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases
MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to two bispecific antibodies,...
World Hemophilia Day 2025 – April 17, 2025 – “Access for all: Women and girls bleed too”
MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global bleeding disorders community will come together under the theme "Access for all: Women and girls bleed too" and celebrate World Hemophilia Day. Today, women and girls with bleeding disorders (WGBDs) are still underdiagnosed and underserved. The global bleeding disorders community has the power—and the responsibility—to change this....
Brain Navi Begins IPO Counseling with First Securities Inc., Setting the Stage for Global MedTech Expansion
ZHUBEI, April 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology Co., Ltd. ("Brain Navi") has officially begun IPO counseling with First Securities Inc., marking a strategic step toward accessing the capital markets and advancing its long-term growth in the surgical robot technology industry. Dr. Jerry Chen, CEO of Brain...
Duke-NUS and T Cells Diagnostics team up to simplify T-cell analysis
Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and management of human infectious diseases. SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its related know-how from Duke-NUS Medical School to develop point-of-care assays that could simplify the analysis...
Fangzhou Launches Partnership for “AI + Hepatitis Prevention & Control Training Center” at the Greater Bay Area International Liver Disease Forum
GUANGZHOU, China, April 17, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven healthcare solutions, partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area International Liver Disease Forum to launch the "AI + Hepatitis Prevention and Control Training Center". This collaboration...
Norgine strengthens rare disease portfolio with acquisition of Theravia
Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising rare and specialty pharmaceuticals in Europe PARIS, April 17, 2025 /PRNewswire/ -- Norgine and Theravia announced...
Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]
IFINWIL®: now TGA registered in Australia Children diagnosed with neuroblastoma are on average just 2 years old2 The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, April 17, 2025 /PRNewswire/ -- Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL®...
